Randomized Controlled Trial
doi: 10.1016/s1166-7087(07)92405-7.
[Sunitinib versus interferon-alpha in metastatic renal-cell carcinoma]
[Article in
French]
Affiliations
- PMID: 17969805
- DOI: 10.1016/s1166-7087(07)92405-7
Item in Clipboard
Randomized Controlled Trial
[Sunitinib versus interferon-alpha in metastatic renal-cell carcinoma]
[Article in
French]
Prog Urol.
2007 Sep.
No abstract available
Similar articles
-
Phase III study of sunitinib malate (SU11248) versus interferon-alpha as first-line treatment in patients with metastatic renal cell carcinoma.Clin Genitourin Cancer. 2006 Jun;5(1):23-5. doi: 10.1016/s1558-7673(11)70151-3. Clin Genitourin Cancer. 2006. PMID: 16859575 Review. No abstract available.
-
[A Cost-effectiveness Analysis of Sunitinib vs. Interferon-alpha in Patient with Advanced Renal Cell Carcinoma in Japan].Yakugaku Zasshi. 2018;138(11):1397-1407. doi: 10.1248/yakushi.17-00189. Yakugaku Zasshi. 2018. PMID: 30381648 Japanese.
-
Sunitinib does not accelerate tumor growth in patients with metastatic renal cell carcinoma.Cell Rep. 2013 Feb 21;3(2):277-81. doi: 10.1016/j.celrep.2013.01.015. Epub 2013 Feb 7. Cell Rep. 2013. PMID: 23395639 Free PMC article. Clinical Trial.
-
Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population.Ann Oncol. 2009 Nov;20(11):1803-12. doi: 10.1093/annonc/mdp067. Epub 2009 Jun 23. Ann Oncol. 2009. PMID: 19549706 Free PMC article. Clinical Trial.
-
Sunitinib for metastatic renal cell carcinoma.Future Oncol. 2010 Sep;6(9):1377-85. doi: 10.2217/fon.10.94. Future Oncol. 2010. PMID: 20919823 Review.
Cited by
-
In Silico Pharmacoepidemiologic Evaluation of Drug-Induced Cardiovascular Complications Using Combined Classifiers.J Chem Inf Model. 2018 May 29;58(5):943-956. doi: 10.1021/acs.jcim.7b00641. Epub 2018 May 10. J Chem Inf Model. 2018. PMID: 29712429 Free PMC article.
-
Comparative efficacy and safety of sunitinib vs sorafenib in renal cell carcinoma: A systematic review and meta-analysis.Medicine (Baltimore). 2020 Mar;99(13):e19570. doi: 10.1097/MD.0000000000019570. Medicine (Baltimore). 2020. PMID: 32221075 Free PMC article.
-
The Efficacy and Safety of Tyrosine Kinase Inhibitors for Von Hippel-Lindau Disease: A Retrospective Study of 32 Patients.Front Oncol. 2019 Nov 1;9:1122. doi: 10.3389/fonc.2019.01122. eCollection 2019. Front Oncol. 2019. PMID: 31737565 Free PMC article.
-
The putative tumour suppressor microRNA-145, repressed by c-jun, modulates clear cell renal cell carcinoma aggressiveness by repressing ROCK1.Int J Clin Exp Pathol. 2018 Jan 1;11(1):138-145. eCollection 2018. Int J Clin Exp Pathol. 2018. PMID: 31938095 Free PMC article.
-
Tumor-suppressing effects of microRNA-429 in human renal cell carcinoma via the downregulation of Sp1.Oncol Lett. 2016 Oct;12(4):2906-2911. doi: 10.3892/ol.2016.4953. Epub 2016 Aug 5. Oncol Lett. 2016. PMID: 27698878 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical